AstraZeneca announced that it would not continue trials of olarparib in ovarian cancer due to the results of the Phase II trial.
The company’s press release is available here
Ovarian Cancer National Alliance • 901 E Street NW, Suite 405 • Washington, DC 20004
(202) 331-1332 • toll-free: 1-866-399-6262 • fax: (202) 331-2292 • email@example.com
All content © Copyright 2014 by Ovarian Cancer National Alliance.
Subscribe to our RSS Feed or view our Sitemap
This site made possible by a grant from Novartis Oncology